Titan Laboratories
Contract pharmaceutical manufacturer and developer established in 2006. Provides formulation development, scale-up and commercial manufacture of solid and semi-solid dosage forms (pellets, granules, tablets, capsules, creams/ointments). Operates high-capacity GMP-compliant manufacturing lines with multiple international regulatory approvals, analytical/QC services, serialization and packaging lines, dedicated potent-area production, and regulatory dossier support (eCTD/EU CTD) for exports to regulated markets.
Industries
Nr. of Employees
medium (51-250)
Titan Laboratories
Products
Finished-dosage-form portfolio (generics and specialty medicines)
Broad portfolio of finished dosage forms across therapeutic areas (tablets, capsules, pellets, granules, creams/ointments) including immediate- and sustained-release forms, DC granules and MUPS; selected products have EU CTD dossiers and additional pipeline products are scheduled for dossier submission between 2026–2028.
Finished-dosage-form portfolio (generics and specialty medicines)
Broad portfolio of finished dosage forms across therapeutic areas (tablets, capsules, pellets, granules, creams/ointments) including immediate- and sustained-release forms, DC granules and MUPS; selected products have EU CTD dossiers and additional pipeline products are scheduled for dossier submission between 2026–2028.
Services
Integrated on-site services from formulation development through scale-up, commercial manufacture, packaging and regulatory support for solid and semi-solid dosage forms.
Laboratory and pilot development for IR/DR/SR/enteric/MUPS and direct compression granules with technology transfer to commercial lines.
On-site QC and analytical testing to support release, stability programs and regulatory submissions (HPLC, dissolution, moisture analysis).
Compilation and maintenance of eCTD/EU CTD dossiers and consultative support for submissions to international regulatory authorities.
Finished-product packaging including blister, alu-alu, bottle and tube lines with 2D matrix printing/verification and anti-tamper integration to support track-and-trace requirements.
Manufacture of potent APIs and controlled substances in dedicated potent-area facilities with regulatory approvals and clearance handling.
Integrated on-site services from formulation development through scale-up, commercial manufacture, packaging and regulatory support for solid and semi-solid dosage forms.
Laboratory and pilot development for IR/DR/SR/enteric/MUPS and direct compression granules with technology transfer to commercial lines.
On-site QC and analytical testing to support release, stability programs and regulatory submissions (HPLC, dissolution, moisture analysis).
Compilation and maintenance of eCTD/EU CTD dossiers and consultative support for submissions to international regulatory authorities.
Finished-product packaging including blister, alu-alu, bottle and tube lines with 2D matrix printing/verification and anti-tamper integration to support track-and-trace requirements.
Manufacture of potent APIs and controlled substances in dedicated potent-area facilities with regulatory approvals and clearance handling.
Expertise Areas
- Contract development and manufacturing (CDMO) for solid and semi-solid dosage forms
- Pellet and granule technologies including MUPS and DC granules
- Formulation development for IR/DR/SR and enteric systems
- Scale-up, process development and technology transfer
Key Technologies
- Fluid-bed coating and drying (top/bottom spray)
- Extrusion and spheronization
- High-speed tablet compression (including bi-layer)
- Capsule filling for pellets, powders and mini-tablets
News & Updates
Recipient of TAB Harmony Award for the years 2020-2021 and 2021-2022.
Recipient of Outstanding Export Award for the years 2014-2015 and 2015-2016.
Recipient of TAB Harmony Award for the years 2020-2021 and 2021-2022.
Recipient of Outstanding Export Award for the years 2014-2015 and 2015-2016.